Table 1. Patient characteristics.
| Variables | Value |
|---|---|
| Number of patients | 31 |
| Patient factor | |
| Age, years [range] | 73 [47-84] |
| Sex, n (%) | |
| Male | 27 (87.1) |
| Female | 4 (12.9) |
| ASA score, n (%) | |
| 1 | 13 (41.9) |
| 2 | 18 (58.1) |
| 3 | 0 (0.0) |
| BMI, kg/m2 [range] | 21.6 [14.6-30.7] |
| AFP, U/mL [range] | 9.0 [1.0-32.5×105] |
| CEA, ng/mL [range] | 9.0 [1.0-5370] |
| CA19-9, U/mL [range] | 100 [69-100] |
| Primary lesion factors | |
| Location, n (%) | |
| Esophagogastric junction | 4 (12.9) |
| Upper | 5 (16.1) |
| Middle | 11 (35.5) |
| Lower | 11 (35.5) |
| Maximum size, cm [range] | 4.0 [0.4-19] |
| Histology, n (%) | |
| Diffuse/other-type adenocarcinoma | 10 (32.3) |
| Intestinal-type adenocarcinoma | 21 (77.7) |
| T classification, n (%) | |
| T1 | 9 (29.0) |
| T2 | 3 (9.7) |
| T3 | 12 (38.7) |
| T4 | 7 (22.6) |
| N classification, n (%) | |
| N0 | 15 (48.4) |
| N1 | 3 (9.7) |
| N2 | 9 (29.0) |
| N3 | 4 (12.9) |
| Liver metastasis factor | |
| Timing of liver metastases, n (%) | |
| Synchronous | 13 (41.9) |
| Metachronous | 18 (58.1) |
| Tumor number, n (%) | |
| 1 | 23 (74.2) |
| 2-3 | 5 (16.1) |
| ≥ 4 | 3 (9.7) |
| Maximum tumor size, cm [range] | 3.1 [0.8-22] |
| Tumor distribution, n (%) | |
| Unilobular | 23 (74.2) |
| Bilobular | 8 (25.8) |
| Preoperative chemotherapy, n (%) | 13 (41.9) |
| Regimen of preoperative chemotherapy, n (%) | |
| S-1 and CDDP | 6 (19.4) |
| CPT-11 and CDDP | 2 (6.5) |
| CPT-11 and MMC | 1 (3.2) |
| S-1 and CDDP and Tmab | 2 (6.5) |
| S-1 and Oxaliplatin | 1 (3.2) |
| CDDP and 5-FU | 1 (3.2) |
| wPTX and Tmab | 1 (3.2) |
Abbreviations: ASA, American society of anesthesiologists; BMI, body mass index; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; S-1, Tegafur gimestat otastat potassium; CDDP, Cisplatin; CPT-11, Irinotecan; MMC, Mitomycin C; Tmab, Trastuzumab; 5-FU, 5-Fluorouracil; wPTX, weekly Paclitaxel.